Please use this identifier to cite or link to this item:
https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3482
Journal Title: | FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer |
Authors: | Paz-Ares, Luis Spigel, David R. Chen, Yuanbin Jove, Maria Juan-Vidal, Oscar Rich, Patricia Hayes, Theresa M. Gutiérrez Calderón, Vanesea Caro, Reyes Bernabe Navarro, Alejandro Dowlati, Afshin Zhang, Bin Moore, Yan Yao, Xiaopan Kokhreidze, Jaba Ponce, Santiago Bunn, Paul |
SWH Author: | Hayes, Theresa M. |
Issue Date: | 2021 |
Date Accessioned: | 2023-03-17T04:57:11Z |
Date Available: | 2023-03-17T04:57:11Z |
Url: | https://dx.doi.org/10.1016/j.jtho.2021.01.126 |
Source Volume: | 16 |
Issue Number: | 3 |
DOI: | 10.1016/j.jtho.2021.01.126 |
Abstract: | Introduction Many patients with small cell lung cancer (SCLC) develop drug resistance to first-line platinum-based chemotherapy, and second-line therapies are limited. RESILIENT (ClinicalTrials.gov identifier NCT03088813) is a two-part phase 2/3 study assessing the safety, tolerability and efficacy of liposomal irinotecan monotherapy as second-line treatment for patients with SCLC. Here we report data from part 1 of the RESILIENT study (data cut off, 2 December 2019). |
URI: | https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3482 |
Journal Title: | Journal of Thoracic Oncology |
Type: | Journal Article |
Appears in Collections: | SWH Staff Publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
J of Thoracic Oncology - 2021 - FP10.04 RESILIENT Part 1 Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer.pdf | 565.61 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.